Azenta (NASDAQ:AZTA) (NASDAQ: AZTA) is a life sciences technology company specializing in advanced sample management, genomic research services and laboratory automation solutions. The company provides critical infrastructure for biopharmaceutical, academic and government research institutions, enabling efficient storage, retrieval and analysis of biological samples. Its offerings span from automated cryogenic storage systems and consumables to high-throughput sequencing, gene synthesis and cell line development services.
Azenta traces its roots to the life sciences division of a legacy automation firm before spinning off as an independent, publicly traded entity in late 2021. The rebranding to Azenta followed several strategic acquisitions, including a leading genomics services provider, which expanded its capabilities in next-generation sequencing and molecular assay development. This evolution has positioned Azenta as a one-stop partner for sample lifecycle management and genomic workflow solutions.
The company’s product portfolio encompasses temperature-controlled sample storage and transportation platforms, automated robotic workstations for liquid handling and assay setup, and a suite of consumables designed for ultra-low temperature and ambient conditions. In addition, Azenta’s genomics services division offers custom DNA synthesis, RNA sequencing, single-cell analysis and bioinformatics support, catering to drug discovery, diagnostic development and personalized medicine projects.
Operating across North America, Europe and the Asia-Pacific region, Azenta serves a diverse customer base that includes pharmaceutical giants, biotech startups and research universities. The business is guided by a seasoned executive leadership team with deep expertise in life sciences, automation engineering and supply chain management. Under the stewardship of President and CEO Bob Chorush, Azenta continues to invest in innovation and global infrastructure to support the accelerating pace of scientific discovery.
